Why the study?
The safety and efficacy of Impella compared with IABP during high-risk PCI had not been evaluated in contemporary practice and remained debated.
Does Impella improve in-hospital survival and reduce complications compared to IABP in patients undergoing nonemergent high-risk PCI?
Does Impella improve in-hospital survival and reduce complications compared to IABP in patients undergoing nonemergent high-risk PCI?
In a real-world propensity-adjusted analysis, Impella use during nonemergent high-risk PCI was associated with improved in-hospital survival and reduced MI and cardiogenic shock compared to IABP.
Answers are grounded in this paper and cite their sources.
May support Impella over IABP in nonemergent high-risk PCI; hypothesis-generating and should not yet change practice.
Impella was approved by the Food and Drug Administration in 2015 for use during high-risk percutaneous coronary interventions (PCIs); however, its safety and efficacy compared with intra-aortic balloon pump (IABP) has not been evaluated in contemporary practice and remains debated. We aimed to compare postapproval outcomes and costs of Impella versus IABP support for high-risk PCI in real-world practice across hospitals in the United States. We identified patients from the Premier Healthcare Database undergoing nonemergent Impella- or IABP-supported high-risk PCI. We used propensity adjustment to control baseline, procedure, and post-PCI medical treatment differences between treatment groups. We included patients undergoing nonemergent single-PCI procedures with either Impella or IABP support and excluded patients presenting with acute ST-elevation myocardial infarction or cardiogenic shock or requiring >1 mechanical support devices during index hospitalization. Outcomes included in-hospital survival, myocardial infarction (MI), cardiogenic shock, stroke, bleeding requiring transfusion, acute kidney injury, index hospitalization length of stay, and costs. From April 2016 to June 2019, a total of 48,179 patients were treated with Impella or IABP mechanical circulatory support at 304 hospitals in the United States. Among these, we identified 2,156 patients undergoing nonemergent high-risk PCI treated with Impella (n = 1,447) or IABP (n = 709). After propensity adjustment, Impella use was associated with improved survival (odds ratio [OR] 1.55, 95% confidence interval [CI] 1.02 to 2.36) and less MI (OR 0.29, 95% CI 0.18 to 0.46) and cardiogenic shock (OR 0.54, 95% CI 0.39 to 0.74). Stroke, bleeding requiring transfusion, and acute kidney injury were similar between groups. In conclusion, this Premier Healthcare Database propensity-adjusted analysis, Impella use during nonemergent high-risk PCI was associated with improved survival and reduced in-hospital MI and cardiogenic shock compared with IABP.
No takes yet. Share an insight, caveat, or question.
Lansky et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: